Blar i Bergen Open Research Archive på forfatter "Hov, Johannes Espolin Roksund"

Viser treff 21-25 av 25

    • NLRP3 inflammasome deficiency attenuates metabolic disturbances involving alterations in the gut microbial profile in mice exposed to high fat diet 

      Sokolova, Marina; Yang, Kuan; Hansen, Simen Hyll; Louwe, Mieke C.; Kummen, Martin; Hov, Johannes Espolin Roksund; Sjaastad, Ivar; Berge, Rolf Kristian; Halvorsen, Bente; Aukrust, Pål; Yndestad, Arne; Ranheim, Trine (Journal article; Peer reviewed, 2020)
      Obesity-related diseases (e.g. type 2 diabetes mellitus and cardiovascular disorders) represent an increasing health problem worldwide. NLRP3 inflammasome activation may underlie obesity-induced inflammation and insulin ...

    • Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency 

      Jørgensen, Silje Fjellgård; Macpherson, Magnhild Eide; Bjørnetrø, Tonje; Holm, Kristian; Kummen, Martin; Rashidi, Azita; Michelsen, Annika; Lekva, Tove; Halvorsen, Bente; Trøseid, Marius; Mollnes, Tom Eirik; Berge, Rolf Kristian; Yndestad, Arne; Ueland, Thor; Karlsen, Tom Hemming; Aukrust, Pål; Hov, Johannes Espolin Roksund; Fevang, Børre (Peer reviewed; Journal article, 2019-01-17)
      Common variable immunodefciency (CVID) patients have reduced gut microbial diversity compared to healthy controls. The reduced diversity is associated with gut leakage, increased systemic infammation and ten “key” bacteria ...

    • Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial 

      Awoyemi, Ayodeji Olawale; Mayerhofer, Cristiane; Felix, Alex S.; Hov, Johannes Espolin Roksund; Moscavitch, Samuel D.; Lappegård, Knut Tore; Hovland, Anders; Halvorsen, Sigrun; Halvorsen, Bente; Gregersen, Ida; Svardal, Asbjørn M.; Berge, Rolf Kristian; Hansen, Simen Hyll; Götz, Alexandra; Holm, Kristian; Aukrust, Pål; Åkra, Sissel; Seljeflot, Ingebjørg; Solheim, Svein; Lorenzo, Andrea; Gullestad, Lars; Trøseid, Marius; Broch, Kaspar (Journal article; Peer reviewed, 2021)
      Background The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast ...

    • Rosuvastatin alters the genetic composition of the human gut microbiome 

      Kummen, Martin; Solberg, Ole Geir; Larsen, Christopher Storm; Holm, Kristian; Ragnarsson, Asgrimur; Trøseid, Marius; Vestad, Beate; Skårdal, Rita; Yndestad, Arne; Ueland, Thor; Svardal, Asbjørn M.; Berge, Rolf Kristian; Seljeflot, Ingebjørg; Gullestad, Lars; Karlsen, Tom Hemming; Aaberge, Lars; Aukrust, Pål; Hov, Johannes Espolin Roksund (Journal article; Peer reviewed, 2020)
      The gut microbiome contributes to the variation of blood lipid levels, and secondary bile acids are associated with the effect of statins. Yet, our knowledge of how statins, one of our most common drug groups, affect the ...

    • Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis 

      Braadland, Peder Rustøen; Schneider, Kai Markus; Bergquist, Annika; Molinaro, Antonio; Lövgren-Sandblom, Anita; Henricsson, Marcus; Karlsen, Tom Hemming; Vesterhus, Mette Nåmdal; Trautwein, Christian; Hov, Johannes Espolin Roksund; Marschall, Hanns-Ulrich (Journal article; Peer reviewed, 2022)
      Background & Aims: Farnesoid X receptor (FXR) agonists and fibroblast growth factor 19 (FGF19) analogues suppress bile acid synthesis and are being investigated for their potential therapeutic efficacy in cholestatic liver ...